Identifying Patients

Who in your practice would benefit from BENLYSTA?

BENLYSTA has been studied in a broad base of patients. Find out which SLE and LN patients would benefit from BENLYSTA. Here are some useful tools:

SELENA-SLEDAI

A tool to assess disease activity in patients with SLE

Download

SLICC/ACR Damage Index

A tool to assess organ damage in patients with SLE

Download

SELENA-SLEDAI TOOL

Use this tool to calculate a patient's score

VIEW TOOL

Consider evaluating your patients with SLE for BENLYSTA if:1-4

  • Patient is 5 years of age or older and has been diagnosed with SLE according to the American College of Rheumatology criteria
  • Patient meets at least 1 of the following:
    • Antinuclear antibody (ANA) titer ≥1:80
    • Anti-dsDNA autoantibodies ≥30 IU/mL
  • Patient is currently receiving any of the following types of standard therapy, alone or in combination, for ≥30 days:
    • Antimalarial
    • Immunosuppressive
    • Corticosteroid
    • NSAID
  • Patient has active SLE*:
    • SELENA-SLEDAI score ≥6 for BLISS-52 and BLISS-76
    • SELENA-SLEDAI score ≥8 for BLISS-SC
  • Patient is not using other biologics
  • Patient does not have severe active CNS lupus

CNS = central nervous system; LN = lupus nephritis; NSAID = nonsteroidal anti-inflammatory drug; SELENA-SLEDAI = Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index; SLE = systemic lupus erythematosus.

* Can include both clinical and serological manifestations of SLE.

eg, arthritis, rash, hair loss.

eg, decreased complement and anti-dsDNA.

Consider evaluating your patients with LN for BENLYSTA if:5

  • Patient is 18 years of age or older and has been diagnosed with lupus nephritis
  • Patient meets at least 1 of the following:
    • Antinuclear antibody (ANA) titer ≥1:80
    • Anti-dsDNA autoantibodies ≥30 IU/mL
  • Patient has clinically active LN requiring induction therapy, confirmed by recent renal biopsy
  • Patient is not using other biologics
  • Patient does not have severe active CNS lupus

Would you consider BENLYSTA for them?

* Hypothetical patient profiles. May not be representative of all BENLYSTA patients.

Meet Laura*

Patient on antimalarial and high-dose steroid

42-year-old patient diagnosed with SLE 2 years ago with persistent arthritis and rash (SELENA-SLEDAI = 6).

Current medications
  • Hydroxychloroquine 300 mg/day
  • Prednisone 15 mg/day
53 %

Did you know that 53% of patients treated with BENLYSTA in 3 phase III clinical trials (BLISS-SC, BLISS-52, and BLISS-76) were not receiving immunosuppressants at baseline?1-3

Meet Ashley*

Patient with lupus nephritis

34-year-old patient diagnosed with SLE 4 years ago, recently diagnosed with lupus nephritis (renal biopsy confirmed Class III lupus nephritis).

Did you know that BENLYSTA can be used in patients with lupus nephritis?
~10 months ago, presented with the following:
  • Proteinuria 2.4 g/24 hours
  • Active urinary sediment
  • Renal biopsy confirmed Class III LN
Induction therapy
  • MMF 2 g/day orally
  • 3 IV pulses of methylprednisolone 750 mg/pulse
    • Followed by oral prednisone 1 mg/kg/day
Maintenance therapy
  • MMF 1 g/day orally
  • Prednisone 5 mg/day

MMF = mycophenolate mofetil.

Meet Sophia*

Pediatric patient with SLE

12-year-old diagnosed with SLE 3 years ago (SELENA-SLEDAI = 9).

Did you know that BENLYSTA IV can be used in patients with SLE as young as 5 years old?6
Current medications
  • Hydroxychloroquine 200 mg/day
  • Prednisone 7.5 mg/day

LN = lupus nephritis; SLE = systemic lupus erythematosus; SELENA SLEDAI = Safety of Estrogens in Lupus Erythematosus: National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index.

Icon: Information

Find the right dosing option for your patient

Learn More

Consider BENLYSTA for appropriate patients with SLE and LN